Kabir Nath, Chief Executive Officer, said, “We continue to progress our two phase 3 trials of COMP360 in treatment-resistant depression with top-line data expected this year and next. While our overall Phase 3 trial completion remains on track with the ‘006 study expected in mid-2025, we are experiencing some enrollment delays in the ‘005 trial, resulting in a slight delay to our guidance for that trial. In parallel, we are actively preparing for commercialization and have commenced a number of collaborations with mental health providers in the US to understand the patient care experience and to investigate models for the delivery of scalable COMP360 psilocybin treatment within various care settings, if approved by the FDA. We are also excited to provide a full data set from our phase 2 study in individuals living with post-traumatic stress disorder this Spring after an initial safety data readout late last year.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CMPS:
- Compass Pathways Announces Fourth Quarter 2023 Financial Results and Business Highlights
- Compass Pathways to participate in upcoming TD Cowen investor conference
- Compass Pathways to announce fourth quarter and year-end 2023 financial results on February 29, 2024
- Here’s What You Missed in Cannabis, Psychedelics This Week
- Rising High: Exclusive talk with cannabis market research firm BDSA